Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1

Abstract excerpt

The PI3K/AKT/mTOR pathway is commonly dysregulated in cancer. Rapalogs exhibit modest clinical benefit, likely owing to their lack of effects on 4EBP1. We hypothesized that bi-steric mTORC1-selective inhibitors would have greater potential for clinical benefit than rapalogs in tumors with mTORC1 dysfunction. We assessed this hypothesis in tumor models with high mTORC1 activity both in vitro and in vivo. Bi-steric...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Renal cell carcinoma treatment
• Share to Tuberous Sclerosis Complex Research